EUVIMEDEUVIMED entdecken
Crossref

Real-World Outcomes of Rapid Drug Desensitization for Taxane and Platinum Chemotherapy

Ferhat Sağun, Fatih Çölkesen, Mehmet Emin Gerek, Seçim Kolak, Emrah Harman, Şükran Aslan Savaş, İsmail Yiğitdöl, Murat Araz, Şevket Arslan

International Archives of Allergy and Immunology · 2026

DOI: 10.1159/000550576 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Archives of Allergy and Immunology, 2026. Verfasst von Ferhat Sağun und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Immunology and Allergy, Department of Internal Medicine, Necmettin Erbakan University Faculty of Medicine, Konya, Turkey. Hauptthemen laut MEDLINE: Desensitization, Immunologic, Drug Hypersensitivity, Taxoids, Antineoplastic Agents. Die Arbeit nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Hypersensitivity reactions (HSRs) to taxane- and platinum-based chemotherapeutic agents are common and may interrupt essential cancer therapy. Rapid drug desensitization (RDD) enables patients to continue treatment safely; however, detailed analyses directly comparing desensitization outcomes between taxanes and platinums remain relatively uncommon. The objective of this study was to describe the clinical characteristics of taxane- and platinum-induced HSRs and to compare desensitization outcomes, breakthrough reactions (BTRs), and graded-challenge success between these drug groups.

Methods

This retrospective study included 27 patients who underwent 30 desensitization procedures, comprising 94 RDD cycles. Standardized 8-, 12-, or 16-step RDD protocols were applied based on the severity of the index reaction and the clinical risk assessment. Demographic and clinical data, characteristics of index HSRs, BTRs during RDD, and outcomes of graded challenges were recorded and analyzed.

Results

Index HSRs most frequently occurred during the first or second infusion (66.6%) and were predominantly moderate in severity (53.3%). Cutaneous symptoms were present in 96.7% of reactions, and anaphylaxis occurred in 30%. Taxane HSRs developed significantly earlier than platinum reactions (69% vs. 24% during the first cycle, p = 0.003). The overall RDD success rate was 97.9%. Seventeen BTRs (18.1%) occurred, most of which were mild (82.4%) and limited to cutaneous involvement (100%). BTRs were significantly more common with platinums than with taxanes (34.8% vs. 2.1%, p < 0.001). Graded challenge was successful more often with taxanes than with platinums (53.8% vs. 17.6%, p = 0.045). No severe or life-threatening BTRs were observed.

Conclusion

RDD enabled the safe continuation of chemotherapy with both taxanes and platinums, with high success rates and infrequent, mostly mild BTRs. Platinum desensitizations carried a higher BTR risk, whereas selected taxane-allergic patients successfully transitioned to graded challenge. These findings support RDD as an effective strategy for managing chemotherapy-induced HSRs and highlight the need for individualized, risk-based protocol selection in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Desensitization, ImmunologicDrug HypersensitivityTaxoidsAntineoplastic AgentsPlatinumHumansFemaleRetrospective StudiesMaleMiddle AgedTreatment OutcomeAdultAgedBridged-Ring Compounds

Stichwörter der Autor:innen

Drug hypersensitivityGraded challengePlatinum compoundsRapid drug desensitizationTaxanes

Substanzen

TaxoidsAntineoplastic AgentstaxanePlatinumBridged-Ring Compounds

Autor:innen und Institutionen

  • Division of Clinical Immunology and Allergy, Department of Internal Medicine, Necmettin Erbakan University Faculty of Medicine, Konya, Turkey.
  • Division of Clinical Immunology and Allergy, Department of Internal Medicine, Necmettin Erbakan University Faculty of Medicine, Konya, Turkey, neueriskinimmunoloji@gmail.com.
  • Division of Medical Oncology, Department of Internal Medicine, Necmettin Erbakan University Faculty of Medicine, Konya, Turkey.

Zitieren

APA

Sağun, F., Çölkesen, F., Gerek, M. E., Kolak, S., Harman, E., Savaş, Ş. A., Yiğitdöl, İ., Araz, M., & Arslan, Ş. (2026). Real-World Outcomes of Rapid Drug Desensitization for Taxane and Platinum Chemotherapy. International Archives of Allergy and Immunology. https://doi.org/10.1159/000550576

Vancouver

Sağun F, Çölkesen F, Gerek ME, Kolak S, Harman E, Savaş ŞA, et al. Real-World Outcomes of Rapid Drug Desensitization for Taxane and Platinum Chemotherapy. International Archives of Allergy and Immunology. 2026. doi:10.1159/000550576

BibTeX
@article{Saun2026,
  author = {Sağun, Ferhat and Çölkesen, Fatih and Gerek, Mehmet Emin and Kolak, Seçim and Harman, Emrah and Savaş, Şükran Aslan and Yiğitdöl, İsmail and Araz, Murat and Arslan, Şevket},
  title = {Real-World Outcomes of Rapid Drug Desensitization for Taxane and Platinum Chemotherapy},
  journal = {International Archives of Allergy and Immunology},
  year = {2026},
  doi = {10.1159/000550576}
}
Kostenlos starten →